CODX vs GSK · rev $3.9M vs P/E 13, $103.31B cap
Co-Diagnostics, Inc. Common Stock (CODX) versus GlaxoSmithKline PLC ADR (GSK) — a side-by-side from cached financials, not a winner call.
Co-Diagnostics, Inc. Common Stock (CODX) is a medical devices company listed on US.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
Latest reported CODX revenue for 2024-12-31 was $3.9M. Net income was -$37.6M. Revenue was down 42.5% from 2023-12-31 to 2024-12-31. CODX currently screens at market cap $31.4M.
GSK does not have a complete income-statement cache yet.
CODX currently screens at market cap $31.4M. GSK currently screens at market cap $103.31B and trailing P/E 13.5.
Not investment advice. Open the CODX and GSK stock pages for the full models.
Not investment advice.